Injectable Weight Loss Medications: What Happens When You Stop?

Most people regain half their lost weight within months of stopping GLP-1 injections. Here's why it happens, what to expect, and how to protect your progress.

Injectable Weight Loss Medications: What Happens When You Stop?

Key Takeaways

  • GLP-1 weight loss injections are effective, but stopping them often leads to significant weight regain — typically half or more of the weight lost
  • Stopping these medications can affect blood sugar, blood pressure, and cholesterol, not just body weight
  • The most common reasons people stop include side effects, high cost, supply shortages, needle aversion, and pregnancy or other health changes
  • Building sustainable lifestyle habits while on the medication is the most evidence-backed strategy for maintaining health gains after stopping
  • Natural supplements that support the body's own GLP-1 production, such as Calocurb®, may help bridge the transition off injectable medications

In recent years, new injectable medications like semaglutide (Wegovy®/Ozempic®) and tirzepatide (Zepbound®/Mounjaro®) have become very popular for weight loss. Often referred to as "skinny shots", these drugs are properly known as GLP-1 receptor agonists (GLP-1 RAs, typically shortened to "GLP-1s" in the popular press). They work by mimicking a hormone in our body called GLP-1, which helps control appetite and blood sugar. GLP-1 naturally rises when we eat; it sends signals to the brain to tell us we're full and to slow down our stomach emptying, both of which help us stop eating more. GLP-1 RAs' popularity is understandable, as they've shown impressive results in clinical trials, helping people with obesity lose 15–21% of their body weight over about a year and a half. 1 2

But what happens if you need to stop taking these medications? Let's explore why people might stop, what to expect, and how to plan for it.

Why Do People Stop Taking Weight Loss Medications?

For those battling overweight and obesity, it's usually a lifelong struggle — much like any other chronic disease, such as hypertension or diabetes. So it's reasonable that doctors expect their patients to require long-term use of GLP-1 RAs to help them reduce weight and then maintain that weight loss. However, the reality is that even people taking them for diabetes — a disease that many regard as a more serious condition than obesity — are more likely to stop GLP-1 RAs than other diabetes drugs. 3 So what are the main reasons people stop them?

Side Effects

The most common reason is stomach and intestinal issues like nausea, diarrhea, and vomiting. Such side effects were 1.5 times more frequent in the main semaglutide clinical trial. 4 They were also more common in the main tirzepatide clinical trial: nausea by 3 times (occurring in 30% of those getting tirzepatide), diarrhea by over 4 times (in 30%) and vomiting by 5 times (in 10%). 5 Less commonly, more severe digestive problems such as bowel obstruction, inflammation of the pancreas and complete loss of stomach emptying have occurred. 6

Other side effects that have nothing to do with the stomach or bowel have also been reported, including hair loss (in around 5%) and mood changes. 7

Cost

These drugs are expensive. In the US, they can cost up to $16,000 per year, and even at maximum discount can be from $3,600–$5,400. 8 What's more, the majority of insurance plans don't cover them for weight loss. 9 These high costs have led to the creation of many sites offering lower-cost versions, but in many cases, these are actually counterfeits or completely different medications. Buyers from such sites in Europe and elsewhere have been hospitalised for extremely low blood sugar, after injecting what they thought was a GLP-1 but turned out to be insulin, prompting global warnings for consumers to be wary. 10

 

Supply Problems

Up until very recently there was a shortage of supply of both semaglutide and tirzepatide, due to high demand. Tirzepatide is apparently no longer in short supply (for now) though semaglutide still is. The supply problems of both these GLP-1 RAs led the FDA to list them officially in their shortage database, which means that compounding pharmacies can make their own versions. However, even though these compounded versions are 'legal' they are not actually approved by the FDA, and in some cases may include ingredient variations that have never been properly studied.

Needle Phobia

These drugs are given by injection just under the skin, which many people find painful or inconvenient. 11 Users also complain about the size of the needle or would prefer to take them by mouth. 12

Reaching Goal Weight

Some people stop once they've lost the weight they wanted to lose, even though rebound weight gain is common with GLP-1 RAs.

Pregnancy or Other Health Changes

Some people need to pause or stop GLP-1 medications due to pregnancy, planned conception, or other significant health changes. These medications are not currently recommended during pregnancy, and patients are typically advised to discontinue them at least two months before attempting to conceive. In these cases, stopping is medically appropriate, but it still requires a transition plan to manage the return of appetite and any associated weight changes.

What Happens When You Stop GLP-1 RAs?

The biggest effect is rebound weight gain. Studies show that people who stop taking these medications often regain about half of the weight they'd previously lost, even though they continued to receive lifestyle coaching. 13 14 In another study of people who stopped taking semaglutide and didn't receive any dietary or exercise advice, they gained back over two-thirds of the weight. 15 This can be frustrating and disappointing.

~50%

Of weight lost typically regained within a year of stopping (with lifestyle coaching)

>66%

Of weight regained when stopping semaglutide without dietary or exercise support

1–2 weeks

How quickly hunger typically returns after the last dose

The two most widely prescribed GLP-1 weight loss medications have both been studied after stopping, and the results are striking:

Medication Brand Names Weight Regain After Stopping How Quickly Hunger Returns
Semaglutide Ozempic, Wegovy Around two-thirds of the lost weight returned within one year of stopping Within 1–2 weeks of the last dose
Tirzepatide Mounjaro, Zepbound More than half of the lost weight returned within one year of stopping Within 1–2 weeks of the last dose

There's also evidence that these drugs might temporarily reduce your body's natural production of GLP-1. In fact, a study that measured natural GLP-1 levels after taking one of the GLP-1 RA injectables for 14 weeks did demonstrate such a drop. 16  The injectables flood the body with very high levels of synthetic versions of GLP-1 for extended periods of time, so it makes sense that the body doesn't see any 'need' to make its own. This suggests that weight gain is even more likely when you stop the medication, because you've not only taken away what helped you lose weight, but you've also damped down your body's natural production of 'stop eating' GLP-1.

Given all that, many people who start GLP-1 RAs may be quite anxious about stopping them. Nevertheless, there are strategies to help manage the aftermath of giving up these drugs.

How to Plan for Stopping GLP-1?

If you're considering these medications, it's important to have an 'exit strategy' before you start, to help you deal with the consequences of stopping them and to reduce any anxiety you may have about them. Here are some tips:

Focus on Lifestyle Changes

The best time to build new habits is while you're still on the medication, not after you've stopped. The appetite suppression window makes it significantly easier to establish routines that will carry you through the transition. Focus on:

  • Protein at every meal. Protein is the most satiating macronutrient and helps preserve muscle mass during weight loss. Aim to make it the anchor of every meal: eggs, meat, fish, legumes, Greek yogurt.
  • Move daily, not occasionally. Resistance training two to three times a week preserves metabolic rate and muscle mass. Walking daily keeps energy expenditure up without requiring gym access.
  • Protect your sleep. Poor sleep directly raises ghrelin, the hunger hormone, and lowers GLP-1. Seven to nine hours is not optional when managing appetite long-term.
  • Reduce ultra-processed foods gradually. These are the foods most likely to trigger overeating once appetite suppression fades. Crowding them out now, while hunger is still managed, is far easier than cutting them out later.

Get Support

The transition off GLP-1 medications is harder alone, and the evidence backs that up. People with professional and social support maintain significantly more weight loss long-term than those going it alone. Consider:

  • A registered dietitian to build a realistic eating plan tailored to your lifestyle before cravings return in full force.
  • A behavioral therapist to address the emotional and psychological side of appetite, food noise, and weight management, particularly if food anxiety or emotional eating have been factors in the past.
  • Your prescribing doctor for a scheduled follow-up within the first month of stopping, not just when something goes wrong.
  • An online community of people navigating the same transition. Peer accountability and shared experience provide practical support that clinical settings don't always offer.

Set Realistic Expectations

It's important to understand the journey of weight loss and maintenance — that it's not a short one — and that some weight gain is normal. Accept that long-term treatment of some sort may be necessary. Try to focus on your overall health, not just the number on the scale.

Even if the scale creeps up after stopping, that doesn't erase the progress you've made. Any weight you manage to keep off continues to work in your favor — keeping your blood pressure lower, your blood sugar more stable, and your cholesterol in a better place. The goal after stopping isn't perfection. It's protection.

Consider Alternatives

What if you could kick-start your body back into making its own GLP-1 after you stop the injectables and even increase the usual amount of GLP-1 your body makes in response to eating? Calocurb is an all-natural, plant-based supplement that does exactly that. It contains Amarasate®, which is a substance extracted from hops grown in New Zealand, where it's been studied for over 14 years in multiple clinical trials (in humans, not lab animals). In one study, Calocurb taken an hour before eating caused GLP-1 to rise to 6 times baseline and twice the usual amount seen with eating — which resulted in the participants eating almost 20% less at the subsequent meal. 17 And during 24-hour water fasts, overall hunger was reduced by 25% in men 18 and by 30% in women. 19 It's been sold in New Zealand for over 5 years, where people have reported weight loss of up to 30 kg (around 60 lbs). Now there's a new study underway looking at weight loss after taking Calocurb for 6 months (and then following up for a further 3 months).

Research also shows that what you eat, how you exercise, and how well you sleep all affect your body's ability to increase GLP-1 naturally over time.

Side effects with Calocurb are rare, but because up to 10% of users may get diarrhea, in general it should be started at a low dose and gradually increased over a few days, aiming to get up to 2 capsules before 2 meals a day.

GLP-1 Injections Calocurb
Mechanism Synthetic GLP-1 analog (external hormone mimic) Stimulates the body's own GLP-1 release
Delivery Weekly subcutaneous injection Oral capsule, taken one hour before meals
Prescription required Yes No
Cost (approx.) $3,600–$16,000/year $89.99/month
Common side effects Nausea, vomiting, diarrhea, constipation (up to 30%) Mild, transient, laxative effect in some users
Clinical backing Large-scale randomized, placebo-controlled trials (thousands of patients) Multiple placebo-controlled human crossover trials (14+ years of research)

Natural GLP-1 support

Bridge the transition off injectable medications

Calocurb contains Amarasate® — a patented New Zealand hops extract backed by 14+ years of human clinical research. It stimulates your body's own GLP-1 release to support appetite control after stopping injectable medications.

Shop now Learn more
Calocurb bottle

To understand how natural and injectable GLP-1 approaches compare in more detail, read our full guide to GLP-1: natural vs injectable approaches. Or if you're weighing up prescription vs natural appetite suppressants more broadly, this guide walks you through the key differences.

Just Stopped? Here's What to Do Now

If you've already taken your last dose, the window to act is now, not after the weight starts coming back. Here are the most important steps to take in the first few weeks:

  • Eat on a schedule, not on instinct. Without the medication keeping appetite suppressed, waiting until you feel hungry to eat often leads to overeating. Switching to structured meal times in the first few weeks, even if you don't feel hungry yet, helps prevent the spike-and-crash hunger cycle that drives early weight regain.
  • Anticipate the return of food noise and plan for it. Know in advance which situations or times of day trigger cravings for you. Having a response plan (a high-protein snack, a walk, a distraction) before the urge hits is more effective than relying on willpower in the moment.
  • Track what you eat for the first few weeks, even loosely. Many people are surprised by how quickly portion sizes drift upward once appetite suppression fades. A simple food diary or app doesn't need to be obsessive; it just creates enough awareness to catch the creep early.

Think of these as your first steps. Maintaining weight loss after stopping injectable weight loss medications for the long term is a different challenge, and one that rewards preparation.

Conclusion

Remember, obesity is a chronic condition, like diabetes or high blood pressure. It often requires long-term management, which may include ongoing medication. GLP-1 medications are FDA-approved for long-term use precisely because the condition they treat is long-term, so if your doctor recommends continuing, that is a clinically sound position. For those who do need to stop, the physical and metabolic health benefits of sustained weight loss are real and worth protecting. If you're thinking about starting or stopping these weight loss drugs, talk to your doctor first to create a plan that's right for you.

Frequently Asked Questions

Can you stop GLP-1 medications cold turkey, or do you need to taper?
GLP-1 medications don't require a formal tapering protocol like some drugs. However, stopping abruptly often triggers a sudden return of appetite. Many clinicians recommend a gradual dose reduction over several weeks to ease the transition. Always speak with your prescribing doctor before making any changes to your medication.
Can I restart GLP-1 medications if I regain weight after stopping?
In most cases, yes — clinical evidence suggests the medications work similarly the second time around. However, restarting requires a new prescription, a reassessment by your doctor, and navigating the same cost and availability hurdles as before. This is one reason why having a maintenance plan after stopping is preferable to relying on restarting.
Is Calocurb safe to use at the same time as GLP-1 medications?
Calocurb works through a different mechanism — stimulating natural gut hormone release via bitter taste receptors — rather than acting directly on GLP-1 receptors. Some practitioners already recommend concurrent use. However, Calocurb should not be taken by individuals with gastrointestinal inflammation or inflammatory bowel disease. Always consult your healthcare provider before combining supplements with prescription medications.
Why am I gaining weight while still taking my GLP-1 medication?
Weight gain on GLP-1 medications can happen for several reasons: your body may have adapted over time, caloric intake may have crept up without you noticing, or the dose may no longer be optimal. If you're gaining weight while still medicated, speak with your doctor before stopping — a dose adjustment may be more appropriate than discontinuing entirely.
Do GLP-1 medications affect digestion after stopping?
Yes. Because GLP-1 medications slow gastric emptying, stopping them can cause noticeable digestive changes as the gut readjusts — including faster digestion, looser stools, or changes in bowel regularity. These effects are temporary and typically stabilize as the medication clears the system. If symptoms are severe or persist beyond a few weeks, speak with your doctor.
Do you lose muscle mass when you stop GLP-1 medications?
Muscle loss is a known concern. Studies suggest a portion of the weight lost on GLP-1 drugs comes from muscle, not just fat. When weight returns after stopping, it tends to come back predominantly as fat, which can leave body composition worse than before starting. 20 This is one of the strongest arguments for maintaining resistance training both during and after treatment.

References

  1. Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity management in adults: a review. JAMA. Nov 28 2023;330(20):2000-2015. doi:10.1001/jama.2023.19897
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New Engl J Med. 2022;387(3). doi:10.1056/nejmoa2206038
  3. Liss DT, Cherupally M, O'Brien MJ, et al. Treatment modification after initiating second-line medication for type 2 diabetes. Am J Manag Care. 2023;29(12):661-668. doi:10.37765/ajmc.2023.89466
  4. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
  5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New Engl J Med. 2022;387(3). doi:10.1056/nejmoa2206038
  6. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023;330(18). doi:10.1001/jama.2023.19574
  7. Manalac T. FDA probes GLP-1 receptor agonists on reports of suicidal thoughts, hair loss. BioSpace. Published January 5, 2024. Accessed April 6, 2024. https://www.biospace.com/article/novo-lilly-weight-loss-drugs-under-fda-scrutiny-for-suicidal-thoughts-hair-loss/
  8. Mozaffarian D. GLP-1 agonists for obesity — a new recipe for success? JAMA. 2024;331(12). doi:10.1001/jama.2024.2252
  9. Winokur Munk C. Most employer health plans don't cover new blockbuster weight loss drugs, but that's going to change. CNBC. Published February 16, 2024. Accessed April 6, 2024. https://www.cnbc.com/2024/02/16/what-you-need-to-know-about-health-coverage-for-new-weight-loss-drugs.html
  10. Lovelace Jr. Berkeley. Health authorities around the globe issue warnings about fake Ozempic. NBC News. Published December 28, 2023. Accessed April 6, 2024. https://www.nbcnews.com/health/health-news/fake-ozempic-health-authorities-globe-issue-warnings-rcna131452
  11. Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;10:403-412. Published 2017 Sep 29. doi:10.2147/dmso.s141235
  12. Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;10:403-412. Published 2017 Sep 29. doi:10.2147/dmso.s141235
  13. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224
  14. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2023;331(1). doi:10.1001/jama.2023.24945
  15. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725
  16. Kim SH, Abbasi F, Nachmanoff C, et al. Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: a randomized controlled trial. Diabetes Obes Metab. 2021;23(2):489-498. doi:10.1111/dom.14242
  17. Walker EG, Lo KR, Pahl MC, et al. An extract of hops (Humulus lupulus L.) modulates gut peptide hormone secretion and reduces energy intake in healthy-weight men: a randomized, crossover clinical trial. Am J Clin Nutr. 2022;115(3):925-940. doi:10.1093/ajcn/nqab418
  18. Walker E, Lo K, Tham S, et al. New Zealand bitter hops extract reduces hunger during a 24 h water only fast. Nutrients. 2019;11(11):2754. doi:10.3390/nu11112754
  19. Walker E, Lo K, Gopal P. Gastrointestinal delivery of bitter hop extract reduces appetite and food cravings in healthy adult women undergoing acute fasting. Obes Pillars. 2024;11:100117. Published 2024 Jun 20. doi:10.1016/j.obpill.2024.100117
  20. Quimbayo-Cifuentes AF. Weight regain after GLP-1-based therapy discontinuation: failure, physiology, or follow-up gap. Cureus. 2026;18(2):e104259. Published 2026 Feb 25. doi:10.7759/cureus.104259
Dr. Tracey Lambert, MBChB, Calocurb

Written by

Dr. Tracey Lambert, MBChB, Calocurb

← Back to blog